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THE CLINICAL USE OF LMP2-SPECIFIC CYTOTOXIC T LYMPHOCYTES
FOR THE TREATMENT OF RELAPSED EBVve HODGKIN DISEASE (HD)
AND NON-HODGKIN LYMPHOMA (NHL)
Bollard, C.M.1, Buza, E.1, Huls, H.1, Lopez, T.1, Gresik, V.1, Chang,
J.2, Gottschalk, S.1, Carrum, G.1, Gee, A.P.1, Brenner, M.K.1, Rooney,
C.M.1, Heslop, H.E.1 1Baylor College of Medicine, Houston, TX; 2The
Methodist Hospital, Houston, TX.
EBV-associated HD and NHL show type II latency expressing
subdominant EBV antigens such as LMP2, which may serve as
targets for immunotherapy. Previously, we used polyclonal EBV-
speciﬁc CTL in patients with relapsed EBV ve HD and saw 2
CRs and 1 PR in 11 patients. We now hypothesize that CTL
speciﬁcally targeting LMP2 might have greater efﬁcacy. LMP2-
CTL were generated using dendritic cells and lymphoblastoid cell
lines which had been genetically modiﬁed to overexpress LMP2 by
transduction with an Ad5f35LMP2 vector. Polyclonal LMP2-
CTL lines recognized 1-7 (median 2) LMP2 epitopes, as deter-
mined using overlapping LMP2 peptide pools in ELISPOT assays.
A mean of 22.8% (5-42.1%) of CD8 T cells bound HLA-
restricted LMP2 multimers, compared to a mean of 0.11% (0.01-
0.24%) in EBV-CTL lines generated from the same patients. So
far, 13 patients have been treated on this dose escalation study—7
patients on DL1 (4  107/m2), 4 on DL2 (1.2  108/m2) and 2 on
DL3 (3  108/m2). No toxicity was observed. After CTL infusion,
an increase in the frequency of EBV  LMP2-speciﬁc T cells
could be detected in the blood in 10/12 evaluated patients (range 2
to 17.6 fold). 6/7 patients who received LMP2-CTL as adjuvant
therapy post SCT or chemotherapy remain in CR up to 24 months
post CTL. 1 patient presented with progressive disease 8 wks post
CTL. 6 patients had detectable disease at the time of CTL therapy
of whom 2 had progressive disease 8 wks post CTL and 4 had
clinical responses (one very good partial response and 3 clinical/
radiologic complete responses). One of these 3 patients was eval-
uated 7 wks after receiving CTLs, which were predominantly CD4
ve (91.6%). Biopsies showed minimal lymphoma cells with in-
creased CD4 ve T cells compared to the pre-CTL biopsy. Im-
aging studies performed 1 wk later were negative for lymphoma.
This patient received 2 extra doses of CTL and re-evaluations
showed CR on PET/CT scans. 2 other patients had stable disease
8 wks post CTL. Both patients received 2 further doses of LMP2-
CTL. One patient is without evidence of disease 14 mths post
CTL. The other patient had a complete radiological response.
This patient had a lymph node resection, which showed selective
accumulation of LMP2-tetramer ve cells (0.3% compared to
0.01% in the peripheral blood) with few residual tumor cells.
Immunotherapy with LMP2-CTL is therefore well tolerated in
patients with EBV ve HD/NHL and infused LMP2-CTL cells
can accumulate at tumor sites and induce clinical responses.
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ORAL BECLOMETHASONE DIPROPIONATE (BDP) FOR GASTROINTES-
TINAL GVHD: A CORTICOSTEROID-SPARING TREATMENT WITH IM-
PROVED SURVIVAL AT DAY 200
McDonald, G.B.1, Cruickshank, S.2, Rodell, T.C.2, Hockenbery, D.M.1
1Fred Hutchinson Cancer Research Center, Seattle, WA; 2DOR Bio-
Pharma, Miami, FL.
Randomized trials show that oral BDP allows rapid tapering of
prednisone while controlling GI GVHD. In Proceedings AACR
2005;45(Suppl):109, the risk of recurrent GVHD was reduced for
the BDP group at study day 50 (HR 0.39, P  .009) and at 30 days
after discontinuation of study drug (HR 0.37, P  .0012). By day
200 post-transplant, 5 BDP patients had died, compared to 16
deaths on placebo. We now examine competing risks for mortality
to determine if randomization to oral BDP was independently
associated with survival. Methods: 129 patients with GI GVHD
were given prednisone 1-2 mg/kg for ten days and oral BDP (8
mg/day) or placebo for ﬁfty days. At study day 10, prednisone was
tapered if GVHD had improved, while continuing study drug. The
survival rate at day 200 was estimated (Kaplan-Meier). The risk of
death for patients treated with BDP relative to placebo was esti-
mated using a Cox proportional hazards model. Multivariate mod-
els determined if the mortality risk reduction attributed to BDP
was still present after accounting for factors thought to modify the
risk of day 200 mortality. Results: The majority of patients had
AML (32%), ALL (12%), or CML (12%). Day 200 survival was
0.92 for the BDP group vs. 0.76 for placebo, P .01. By transplant
day 200, relapse of hematologic malignancy had contributed to
deaths of 9/67 patients (13.4%) in the placebo arm and 3/62
patients (4.8%) in the BDP arm. Infection contributed to deaths of
9/67 (13.4%) in the placebo arm and 3/62 (4.8%) in the BDP arm.
By univariate analysis, the risk of mortality during this period was
66% lower with BDP treatment compared to placebo (hazard ratio
0.34, P  .0376). With the exception of BDP treatment (HR 0.35,
P  .05), none of the factors in a multivariate model were signif-
icantly associated with day 200 survival (Table 1). Patients who
experienced recurrent GVHD during the study had 1) greater
corticosteroid exposure (47.6  31 mg/kg vs. 20.1  11 mg/kg,
P  .0001); and 2) a greater risk of death to day 200 (hazard ratio
3.15, P  .0138). There was a 2% incremental increase in the risk
of death for every 1.0 mg/kg increase in cumulative prednisone
exposure relative to the lowest exposure observed (HR 1.02, P 
.0458). Conclusions: Oral BDP allows prednisone to be rapidly
tapered with fewer recurrences of gastrointestinal GVHD. Re-
duced day 200 mortality in the BDP arm was likely related to
avoidance of prolonged prednisone therapy and thus, fewer fatal
infections and relapses of leukemia.
Table 1. Multivariate Model for the Duration of Survival 200 Days
after Transplant
Variable Hazard Ratio (C.I.) P Value
Beclomethasone
dipropionate
0.35 (0.12, 1.004) .05
Matched sibling donor 0.48 (0.20, 1.16) .10
Age per 1 year
increase
1.03 (1.03, 1.07) .20
Marrow as stem cell
source
0.53 (0.07, 4.35) .56
Male 1.23 (0.50, 3.03) .66
Diagnosis with elevated
risk of relapse*
1.27 (0.49, 3.29) .63
Non-myeloablative
conditioning
0.70 (0.24, 2.01) .50
Random center effect Variance  0.18
1BB&MT
*Patients were considered to be at high risk of relapse following
transplant if the indication for transplant was one of these diag-
noses: AML other than 1st remission, CML other than CP; ALL;
APL; and lymphoma. Patients with other diagnoses were consid-
ered to be at low risk. The variable for BDP was deﬁned in the
model as a time dependent covariate. The hazard ratio was esti-
mated for each variable from a multivariate Cox model.
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MESENCHYMAL STEM CELLS FOR TREATMENT OF SEVERE ACUTE
GRAFT-VERSUS-HOST DISEASE
Ringden, O.1,2, Uzunel, M.1,2, Rasmusson, I.2, Remberger,
M.1,2, Sundberg, B.1,2, Lonnies, H.1,2, Marschall, H.U.3, Dlugosz,
A.3, Szakos, A.4, Hassan, Z.1, Omazic, B.1,2, Aschan, J.1, Barkholt,
L.1, Le Blanc, K.1,2 1Center for Allogeneic Stem Cell Transplantation,
Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm,
Sweden; 2Division of Clinical Immunology, Karolinska Institutet, Karolin-
ska University Hospital Huddinge, Stockholm, Sweden; 3Department of
Gastroenterology, Karolinska Institutet, Karolinska University Hospital
Huddinge, Stockholm, Sweden; 4Division of Pathology, Karolinska Institu-
tet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Mesenchymal stem cells (MSC) derived from adult bone marrow
can differentiate into several mesenchymal tissues and they also
have immunomodulatory effects. We gave MSC to eight patients
with steroid-refractory grades III-IV acute graft-versus-host dis-
ease (GVHD) and one who had extensive chronic GVHD. The
MSC dose was median 1.0 (range 0.7 to 9)  106/kg body weight
of the recipient. No acute side-effects occurred after the MSC
infusions. Six patients were treated once, three patients twice,
one was given a second infusion for a recurrence of GVHD and
two showed a poor response shortly after the ﬁrst infusion. Two
patients received MSC from HLA-identical siblings, six from
haplo-identical family donors and four from unrelated mis-
matched donors. Acute GVHD disappeared completely in six of
eight patients. One of these developed cytomegalovirus gastro-
enteritis. Two died soon after this treatment and therefore the
response could not be evaluated, but one had MSC donor DNA
in the colon and a lymph node. Five patients are still alive
between 2 months and 3 years after the transplantation. Their
survival rate was signiﬁcantly better than that of 16 patients with
steroid-resistant biopsy-proven gastrointestinal GVHD, not
treated with MSC during the same period (P  .03). One patient
treated for extensive chronic GVHD showed a transient re-
sponse in the liver, but not in the skin and he died of Epstein-
Barr virus lymphoma. In conclusion, MSC is a very promising
treatment for severe steroid-resistant acute GVHD.
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